Abstract :
Novel therapies that optimize lipid metabolism to reduce the risk of atherosclerotic cardiovascular disease (ASCVD) include PCSK-9 inhibitors, bempedoic acid, icosapent ethyl and inclisiran. These treatments are considered when lifestyle modifications and statin therapy are not enough to achieve adequate ASCVD risk reduction.